Hexamethylmelamine as a single agent in the treatment of small-cell carcinoma of the lung

Publisher Website
Google Scholar
Abstract
In phase II trials, hexamethylmelamine treatment of patients with small-cell carcinoma of the lung achieved response rates of 42 and 37%. At neither institution was there a significant improvement in survival for responders compared to nonresponders. Nausea and vomiting were reported by .apprx. 3/4 of the patients. Severe leukopenia was seen in 3 of 45 patients.